The effect of PTH(1–84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

(2010) Kenneth F Schulz et al.   BMC Medicine

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats

(2010) Pierre J. Marie et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture

(2010) S. Ferrari   OSTEOPOROSIS INTERNATIONAL

Using biochemical markers of bone turnover in clinical practice

(2009) F. R. SINGER et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?

(2009) Glen M Blake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis*

(2009) Robert R Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Interpreting Change Scores for Pain and Functional Status in Low Back Pain

(2009) Raymond W. J. G. Ostelo et al.   SPINE

Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84

(2008) R.R. Recker et al.   BONE

Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window

(2008) John P. Bilezikian   Current Osteoporosis Reports